HYPOMAP snRNASeq - Tadross data

• IRB DUO:0000021 (version: 2021-02-23)ethics approval requiredThis data use modifier indicates that the requestor must provide documentation of local IRB/ERB approval.
• MOR DUO:0000024 (version: 2021-02-23)publication moratoriumThis data use modifier indicates that requestor agrees not to publish results of studies until a specific date.
• GRU DUO:0000042 (version: 2021-02-23)general research useThis data use permission indicates that use is allowed for general research use for any research purpose.

DATA TRANSFER AGREEMENT for Human HYPOMAP

NON NEGOTIABLE UNIVERSITY OF CAMBRIDGE DATA TRANSFER AGREEMENT – OUTGOING Provider (Cambridge) The Chancellor, Masters, and Scholars of the University of Cambridge of The Old Schools, Trinity Lane, Cambridge CB2 1TN, UK Provider Scientist Professor Giles S. H. Yeo Professor of Molecular Neuroendocrinology University of Cambridge, Department of Clinical Biochemistry, Addenbrookes Hospital, BOX 289, Hills Road, Cambridge, CB2 0QQ, UK. Contact : Mr Phinda Dube (Phinda.Dube@admin.cam.ac.uk) Recipient [INSERT NAME] with official registration number [INSERT NUMBER] of [INSERT ADDRESS] Recipient Scientist [INSERT NAME], [INSERT JOB TITLE] of [INSERT CONTACT ADDRESS] [INSERT EMAIL] Data means the data described in Schedule A Research Project means the research project described in Schedule B Parties means Cambridge and the Recipient Cambridge agrees to provide, and the Recipient agrees to receive and use the Data for the Research Project in accordance with the terms and conditions set out in this Agreement. AGREED by the Parties through their authorised signatories: For and on behalf of The Chancellors, Masters, and Scholars of the University of Cambridge Signed Print Name Date For and on behalf of [INSERT RECIPIENT] Signed Print Name Date Read and understood by the Recipient Scientist Signed Print Name Date Terms and Conditions 1. Definitions 1.1 Data: means the data described in Schedule A (which includes Personal Data). 1.2 EGA: means The European Genome-phenome Archive. 1.3 UK Data Protection Laws: means all laws relating to data protection, the processing of Personal Data, privacy and/or electronic communications in force from time to time in the UK including the UK GDPR and the Data Protection Act 2018. 1.4 Personal Data: shall have the meaning given in the UK Data Protection Laws. 1.5 Process: shall have the meaning given in the UK Data Protection Laws. 1.6 Research Project: means the research project described in Schedule B. 1.7 Results: means all information, techniques, data, results, design, technology, materials, inventions, algorithms and software identified or first reduced to practice or writing in the course of undertaking the Research Project. 1.8 UK GDPR has the meaning given to it in section 3 of the Data Protection Act 2018. 2. Use of Data 2.1 Cambridge confirms that it is entitled to provide the Data to the Recipient for use as described in this Agreement. Nothing in this Agreement shall affect the ownership of the Data. 2.2 Cambridge grants the Recipient a non-exclusive, non-transferable licence to use the Data solely for the Research Project in accordance with this Agreement. All other rights are reserved. 2.3 The Recipient undertakes: 2.3.1 to use the Data solely for the Research Project in accordance with this Agreement and all applicable laws; 2.3.2 subject to clause 2.3.9 to restrict access to the Data to the Recipient Scientist and the individuals working under the Recipient Scientist’s direct supervision, and to ensure that those individuals are aware of and comply with this Agreement; 2.3.3 to keep the Data confidential and subject to clause 2.3.9 not to sub-licence, transfer, disclose or otherwise make the Data available in whole or in part to any third party; 2.3.4 to refer to EGA any request for the Data from anyone other than the individuals working under the Recipient Scientist's direct supervision; 2.3.5 to keep the Data secure by implementing organisational and technological measures appropriate to the nature and sensitivity of the Data to protect against the unauthorised or accidental access, use or disclosure of the Data; 2.3.6 to notify Cambridge as soon as reasonably practicable after becoming aware of any unauthorised or accidental access, use or disclosure of the Data and to cooperate with any investigation made by Cambridge in connection with such access, use or disclosure; 2.3.7 not to attempt to re-identify any individual from the Data or to communicate with any individual re-identified from the Data, or to link or attempt to link the Data to other data or information if doing so might identify any individual; 2.3.8 to Process the Data in accordance with UK Data Protection Laws and to comply with Schedule C; and 2.3.9 to delete all copies of the Data from its hard drives and moveable media and destroy all physical copies of the Data as soon as reasonably practicable on termination of this Agreement This obligation does not extend to automatically generated computer back-up or archival copies generated in the ordinary course of the Recipient’s information systems procedures, provided that the Recipient makes no further use of those copies. 3. Confidentiality & Publication 3.1 The Recipient will not be in breach of any obligation to keep the Data confidential if the Data: a) enters the public domain through no improper act of the Recipient; b) must be disclosed for minimum lawful compliance with court orders, regulations or statutes, provided in all cases Cambridge is notified as early as possible prior to disclosure. 3.2 The Recipient agrees to follow the Publication Policy in Schedule B. This includes respecting the moratorium period for Cambridge to publish the first peer-reviewed report describing and analysing these Data. 4. Results 4.1 The Recipient agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 4.2 The Recipient shall promptly notify Cambridge of any application for patent or other proprietary rights to protect intellectual property contained in the Results. The Recipient shall not use the Results for any commercial purpose without the prior written consent of Cambridge. 5. Termination 5.1 This Agreement will terminate on the earliest of the following dates: (a) completion of the Research Project; or (b) expiry of thirty days written notice from one Party to the other. 5.2 Without prejudice to clause 5.1, Cambridge may terminate this Agreement with immediate effect by written notice to the Recipient if the Recipient is in material breach of this Agreement and the breach: (a) cannot be remedied; or (b) can be remedied, but the Recipient fails to do so within 30 days starting on the day after receipt of written notice. 5.3 Any provision of this Agreement that expressly or by implication is intended to survive termination of this Agreement including but not limited to the Recipient’s obligations in clause 2.3.7 shall remain in full force and effect. 6. Liability 6.1 Except as provided in clause 2.1, Cambridge provides the Data “as is” and makes no representation and gives no warranty of any kind either express or implied in relation to the Data, including but not limited to warranties of accuracy or fitness for a particular purpose, or that the Data will not infringe any patent, copyright, trademark or other proprietary rights, accordingly Cambridge will not be liable for any loss arising from any reliance placed on the Data by the Recipient. 6.2 Cambridge will not be liable to the Recipient for any use made of the Data by the Recipient, including but not limited to any claim made against the Recipient by a third party due to or arising from the use, handling, storage or disposal of the Data by the Recipient. Subject to clause 2.1, the Recipient agrees to be liable for any loss, damage, claim and other liability of whatsoever kind or nature due to or arising from its use, handling, storage or disposal of the Data. 6.3 Nothing in this Agreement limits or excludes either Party’s liability for (a) death or personal injury resulting from negligence, (b) fraud or fraudulent misrepresentation, or (c) for any other liability which by law cannot be limited or excluded. 6.4 The liability of either Party for any breach of this Agreement will not extend to loss of business or profit or to any indirect or consequential loss or damage. 6.5 The Recipient agrees that Cambridge, and all other parties involved in the creation, funding or protection of these Data: a) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data 7. General 7.1 Costs: The Data is provided at no cost. 7.2 Assignment: The Recipient may not assign or transfer this Agreement or any of its rights or obligations under it without the prior written consent of Cambridge. 7.3 Entire Agreement: This Agreement constitutes the entire agreement between the Parties and supersedes all negotiations, understandings or previous agreements between the Parties relating to its subject matter. 7.4 Third Parties: A person who is not a Party to this Agreement shall not have any rights under or in connection with it. 7.5 Governing Law: This Agreement is governed by and shall be construed in accordance with English law. The English courts shall have exclusive jurisdiction to deal with any dispute which may arise out of or in connection with this Agreement, except that either Party may bring proceedings for an injunction in any jurisdiction. 7.6 Escalation: Either Party may give a dispute notice to the other to escalate any dispute under this Agreement for joint resolution by senior representatives of the Parties. Either Party may litigate if the dispute has not been resolved within twenty-eight (28) days beginning on the date of the dispute notice. Either Party may apply for an injunction whether or not any dispute has been escalated under this clause. 7.7 Counterparts: This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed electronically using Docusign and delivered by email. [END] Schedule A The Data These data were generated by the University of Cambridge in a Study led by Professor Giles Yeo entitled ‘A comprehensive spatio-cellular map of the human hypothalamus’ on profiling the spatio-cellular architecture of the human hypothalamus by single-cell and spatial transcriptomic profiling. Dataset reference (EGA Study ID and Dataset Details) EGAD50000000997, HYPOMAP snRNASeq - Tadross data G131787/ EGAD50000000997 / doi:10.1038/s41586-024-08504-8 Names of other Data Providers/collaborators Prof. Jens Brüning – Max Planck Institute for Metabolism Research, Cologne, Germany Categories of data subjects whose data is transferred Research Participants – individuals who have given fully informed valid consent to the Provider for the processing of their personal data and for the sharing of said data with bona fide researchers for specific research purposes Categories of data transferred Special Category Data – Genetic data of research participants together with basic demographic and clinical data Provider’s lawful basis for sharing Personal Data Personal Data: • Legitimate Interests (Article 6(1)(f) UK GDPR) Special Categories of Data: • Scientific research purpose (Article 9(2)(j) UK GDPR Nature of the processing For the purpose of the Research Project described in Schedule B The Data released from EGA Services will be analysed as described in the research project. File access: Data can be held in unencrypted files on an institutional compute system, with Unix user group read/write access for one or more appropriate groups but not Unix world read/write access behind a secure firewall. Laptops holding these data should have password protected logins and screenlocks (set to lock after 5 min of inactivity). If held on USB keys or other portable hard drives, the data must be encrypted. Schedule B The Research Project [INSERT DESCRIPTION OF THE RESEARCH PROJECT] [RECIPIENT TO COMPLETE] Details of dataset requested i.e., EGA Study and Dataset Accession Number Brief abstract of the Project in which the Data will be used (500 words max) All Individuals who the User Institution to be named as registered users Name of Registered User Email Job Title Supervisor* All Individuals that should have an account created at the EGA Name of Registered User Email Job Title PUBLICATION POLICY Cambridge intends to publish the results of their analysis of this dataset and do not consider its deposition into public databases to be the equivalent of such publications. Cambridge anticipates that the dataset could be useful to other qualified researchers for a variety of purposes. However, some areas of work are subject to a publication moratorium. The publication moratorium covers any publications (including oral communications) that describe the use of the dataset. For research papers, submission for publication should not occur until 1 month after these data were first made available on the relevant hosting database unless Cambridge has provided written consent to earlier submission. In any publications based on these data, please describe how the data can be accessed, including the name of the hosting database (e.g., The European Genome-phenome Archive at the European Bioinformatics Institute) and its accession numbers (e.g., EGAS00000000029), and acknowledge its use in a form agreed by the User Institution with Cambridge. Schedule C Personal Data: security obligations 1. The Recipient shall be clear about who is responsible for ensuring information security and other provisions for the protection of Personal Data. 2. The Recipient shall ensure that appropriate security measures including technical and organizational measures are in place at all times and backed up by robust policies and procedures to protect the Personal Data (copies to be provided to Cambridge on request). Such measures shall include without limitation: o providing an appropriate level of information governance for all Personal Data; o ensuring that the hardware and software used in Processing the Personal Data are reliable and protected against all kinds of malicious software and viruses; o ensuring the method of storing Personal Data is secure and controlling access to the Personal Data; o using password protection on computer systems on which Personal Data is stored; o taking reasonable steps to ensure the reliability of individuals who have access to the Personal Data, including but not limited to ensuring all such individuals understand the confidential nature of the Personal Data and the issues which arise if proper care is not taken in the use of the Personal Data and that all such individuals are properly trained in how to comply with UK Data Protection Laws prior to accessing the Personal Data; o properly controlling remote access and ensuring that Personal Data is not downloaded to portable devices unless strictly necessary and only then if encrypted; and o having a secure method for the deletion and disposal of Personal Data in whatever form. 3. The Recipient shall have in place systems for swiftly and efficiently detecting, investigating and remedying Personal Data breaches (as defined in the UK Data Protection Laws), and promptly reporting any such breaches to Cambridge. 4. In the case of Personal Data concerning health, the Recipient shall meet the appropriate requirements of the NHS Digital Data Security and Protection Toolkit or equivalent level of information governance